Detailed Study Description

The primary purpose of this study is to demonstrate improvements in lung function for subjects treated with UMEC/VI compared with UMEC for 24 weeks. The effect of UMC/VI, UMEC, and salmeterol with respect to patient HRQoL measured through patient reported outcomes (PROs) Questionnaires, symptoms and lung function will also be evaluated